Discover why Hims & Hers is leading the telehealth market with strong growth, a loyal user base, and expansion into new ...

Eli Lilly found itself in a pharmaceutical pickle after its CFO claimed telehealth partners don’t compound key weight-loss ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Officials at the FDA say they want to speed up approvals for new drugs and devices using tech like the new "Elsa" AI system. More news is on other uses of AI in health care, Eli Lilly refusing to work ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today ...

Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...